Osiris Clinical Study
Osiris Clinical Study Shows Promise for Osteoarthritis Pain Sufferers
Columbia, MD-based Osiris Therapeutics Inc. announced yesterday a positive one-year interim result in the evaluation of Chondrogen, a preparation of adult stem cells formulated for direct injection into the knee.
Data from the one-year Phase I/II double-blind, controlled study of 55 patients evaluating the safety and exploratory effectiveness of Chondrogen in patients undergoing surgery to remove a torn meniscus, showed improvement in joint condition that correlated with a clinically and statistically significant improvement in pain in patients with osteoarthritis (OA) who received Chondrogen as compared to those treated with the control, hyaluronic acid (HA). See full press statement.
Osiris's investment in clinical trials would not be feasible without patents protecting its core technology. Osiris owns several patents relating to the use of adult stem cells, including its base patent U.S. Pat. No. 5,486,359, entitled "Human Mesenchymal Stem Cells" (1996), which claims "An isolated, homogeneous population of human mesenchymal stem cells which can differentiate into cells of more than one connective tissue type." Other Orisis patents include U.S. Pat. No. 6,835,377, entitled "Osteoarthritis Cartilage Regeneration" (2004), which claims "A method for regenerating articular cartilage defects in a host in need thereof, comprising administering to said host cultured human mesenchymal stem cells, said human mesenchymal stem cells having a fibroblastic morphology."
See related articles: Maryland Daily Record, Baltimore Business Journal
